Arie Belldegrun

Diamante Closes Euro 595,000 Seed Round Led by Arieli Capital

Retrieved on: 
Tuesday, January 17, 2023

VERONA, Italy, Jan. 17, 2023 /PRNewswire/ -- Diamante S.r.l., a female-led Italian biotechnology company focused on the use of plants for producing high value-added molecules, closes Euro 595K as a second Seed Round led by Arieli Capital. Offering value for global markets, Diamante is creating a groundbreaking health technology with the power to improve the health of millions of people around the world.

Key Points: 
  • , a female-led Italian biotechnology company focused on the use of plants for producing high value-added molecules, closes Euro 595K as a second Seed Round led by Arieli Capital .
  • Offering value for global markets, Diamante is creating a groundbreaking health technology with the power to improve the health of millions of people around the world.
  • Diamante was founded in 2016 with the development of new tools in autoimmune disease diagnosis and is now expanding into therapeutics applications.
  • Since our goal is to build a healthy and agile corporate environment, including in our team, Arieli Capital will open doors for us like never before.

A Leading Healthcare venture capital fund NGT Healthcare2 welcomes Arieli Capital as a Partner

Retrieved on: 
Wednesday, September 7, 2022

TEL AVIV, Israel, Sept. 7, 2022 /PRNewswire/ -- Arieli Capital joins NGT Healthcare2 ("NGT"), a health-tech venture capital fund based in Nazareth, as a Partner. The second fund will allow NGT to invest around $100 million in breakthrough technologies from academic and medical institutions, with an emphasis on promoting entrepreneurship within the Arab community.

Key Points: 
  • TEL AVIV, Israel, Sept. 7, 2022 /PRNewswire/ -- Arieli Capital joins NGT Healthcare2 ("NGT"), a health-tech venture capital fund based in Nazareth, as a Partner.
  • "We at Arieli Capital believe in promoting technologies that have the potential to improve the lives of millions of people around the world," said Or Haviv, Partner and Head of Global Innovation at Arieli Capital.
  • "We are happy to have Arieli Capital join us as a Partner, which expands our extensive network of connections.
  • The second fund with $100 million will invest in approximately 25 additional early-stage start-up companies and 16 'year zero' projects.

Arieli Capital & The Bridge announce Well4Tech Bootcamp

Retrieved on: 
Monday, February 28, 2022

TEL AVIV, Israel, Feb. 28, 2022 /PRNewswire/ -- The global wellness industry is growing at an impressive pace, currently turning $4.5 trillion in revenues annually (source: GWI). Meanwhile, the term healthcare has grown to include numerous areas that benefit from the accelerated innovation and technological evolution of the past few years, including personal care, beauty, and anti-aging ($1 billion); food and healthcare - $700 billion; including physical and mental wellness $640 billion.

Key Points: 
  • Arieli Capital , US-based holdings, and investment company, and The Bridge, a US Healing & Arts Center, based in Farmington CT, are launching Well4Tech Bootcamp , an international program focused on Innovation in the field of physical and mental health.
  • The Bootcamp will take place at the Bridge Healing Arts Center facilities in Connecticut and New York, the USA, in May 2022.
  • Arieli Capital is a holding & investment firm with offices in New York and Tel Aviv.
  • The Bridge Healing Arts Center is Connecticut's premier healing arts destination for all seeking a state of health and mindfulness.

UroGen Pharma to Report Second Quarter 2021 Financial Results on Wednesday, August 4, 2021

Retrieved on: 
Wednesday, July 28, 2021

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021, prior to the open of the market.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021, prior to the open of the market.
  • The announcement will be followed by a live audio webcast and conference call at 8:30 AM Eastern Time.
  • The webcast will be made available on the Investors section of the Companys website at http://investors.urogen.com .
  • UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options.

Oncology Pharma Reveals Strategic Plans for Company Growth and Focus

Retrieved on: 
Tuesday, March 16, 2021

SAN FRANCISCO, CA, March 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire Oncology Pharma, Inc. (OTC: ONPH) revealed today the Companys plans for growth and development of its intellectual property and business model.

Key Points: 
  • SAN FRANCISCO, CA, March 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire Oncology Pharma, Inc. (OTC: ONPH) revealed today the Companys plans for growth and development of its intellectual property and business model.
  • Also, an important part of the Companys strategic plans include the goal of forming financial partnerships that allow the development of licensed therapeutic agents.
  • ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the "Company") is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
  • For additional information, please contact the Oncology Pharma at:

UroGen Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021

Retrieved on: 
Thursday, March 11, 2021

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, March 18, 2021, prior to the open of the market.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, March 18, 2021, prior to the open of the market.
  • The announcement will be followed by a live audio webcast and conference call at 8:30 AM Eastern Time.
  • The webcast will be made available on the Investors section of the Companys website at http://investors.urogen.com .
  • UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options.

Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors

Retrieved on: 
Tuesday, January 26, 2021

Additionally, the company announced that Rebecka Belldegrun, M.D., has resigned from the board to pursue other opportunities.

Key Points: 
  • Additionally, the company announced that Rebecka Belldegrun, M.D., has resigned from the board to pursue other opportunities.
  • On behalf of the board of directors and senior management team at Kronos Bio, I am pleased to welcome Marianne to the board.
  • I would also like to thank Rebecka for her dedicated service to Kronos Bio.
  • At Kronos Bio, she will serve as a member of the board of directors compensation committee.

UroGen Pharma to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020

Retrieved on: 
Monday, November 2, 2020

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report third quarter 2020 financial results on Monday, November 9, 2020, prior to the open of the market.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report third quarter 2020 financial results on Monday, November 9, 2020, prior to the open of the market.
  • The announcement will be followed by a live audio webcast and conference call at 8:30 AM Eastern Time.
  • The webcast will be made available on the Investors section of the Companys website at http://investors.urogen.com .
  • UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options.

UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

Retrieved on: 
Monday, August 3, 2020

UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases, today announced that it will report second quarter 2020 financial results on Monday, August 10, 2020, prior to the open of the market.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases, today announced that it will report second quarter 2020 financial results on Monday, August 10, 2020, prior to the open of the market.
  • The announcement will be followed by a live audio webcast and conference call at 8:30 AM Eastern Time.
  • The webcast will be made available on the Investors section of the Companys website at http://investors.urogen.com .
  • UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options.

UroGen Pharma to Report First Quarter 2020 Financial Results On Thursday, May 7, 2020

Retrieved on: 
Friday, May 1, 2020

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will report first quarter 2020 financial results on Thursday, May 7, 2020, prior to the open of the market.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will report first quarter 2020 financial results on Thursday, May 7, 2020, prior to the open of the market.
  • The announcement will be followed by a live audio webcast and conference call at 8:30AM Eastern Time.
  • The webcast will be made available on the Investors section of the Companys website at http://investors.urogen.com .
  • UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options.